Press release
Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting
Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient with
About this update from Compugen Ltd.
[{"type":"text","content":"Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient with prior progression on Opdivo®\n Preliminary biomarker data reveal immune activation evidenced by a trend of increased proliferation of peripheral CD8 + effector memory T cells, NK-T cells, and increased serum IFNγ\n Anti-tumor activity also observed in PD-L1 low, PVRL2 positive patients, suggesting COM701 treatment may drive anti tumor immunity even in non-inflamed tumors\n\n\nHOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab) in an oral presentation at the ASCO 2021 Annual Meeting, being held virtually on June 4-8, 2021. COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by Compugen.\n\"These new data from our COM701 clinical program are meaningful for two key reasons,\" said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. \"First, durability data show multiple patients on treatment beyond one year, strengthening our confidence that PVRIG blockade through COM701 may provide meaningful clinical benefit in tumor types typically unresponsive to immune checkpoint inhibitors, including in patients with prior progression on these treatments. Our ongoing confirmed complete response from the combination arm is particularly noteworthy given it was achieved in a patient with anal squamous cell carcinoma with prior progression on Opdivo® and is on study treatment now out to 22 months. We believe these results support our hypothesis that dual blockade of PVRIG and PD-1 may be key to driving immune responses in certain patient populations.\" \nDr. Cohen-Dayag continued, \"Second, preliminary biomarker data provide important insights into the mechanism of COM701 immune activation. A trend of increased peripheral immune cell proliferation of CD8+ effector memory T cells and NK-T cells was observed in the monotherapy and combination arms. In addition, increased levels of the key antitumor cytokine IFNγ, observed with inc...